Margaret Han Dugan
Member of Scientific Advisory Committee & Independent Non-Exec. DirectorDr. Margaret Han Dugan, M.D. has been the Chief Medical Officer at Whitehawk Therapeutics, Inc. since December 2025. She joined Schr?dinger, Inc. in 2023 and served as its Chief Medical Officer since July 2023 until 2025. She serves as Member of Scientific Advisory Board and Commercial & Medical Affairs Advisory Committee of BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) and is its Independent Non-Executive Director from June 11, 2026. She is Member of Scientific Advisory Board at SonALAsense, Inc. She has led several drug development programs in oncology through FDA approval, including temozolomide, the standard of care in GBM. She is Independent Non-Executive Director of BeOne Medicines Ltd. (formerly known as BeiGene, Ltd.) from February 01, 2022. Dr. Dugan is currently Chief Medical Officer at Dracen Pharmaceuticals. She joined Dracen in 2018 with experience in oncology and previously held senior leadership roles at Novartis Oncology, including Senior Vice President and Global Program Head, developing innovative medicines for patients. Dr. Dugan also held several development positions at Schering-Plough (now Merck & Co.) and American Cyanamid (now Pfizer). Dr. Dugan received her B.A. and medical degrees and training in hematology and oncology from New York University.
Positions
- Company NameBeOne Medicines AGStock Code06160PositionMember of Scientific Advisory Committee & Independent Non-Exec. DirectorRelated SecuritiesColleagues
- JVJohn V. OylerCo-Founder, Executive Chairman & CEO
- WLWang LaiPresident and Global Head of Research & Development
- XWXiaodong WangCo-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder
- ARAaron RosenbergChief Financial Officer
- CLChan LeeGeneral Counsel, Senior VP & Corporate Secretary
- ACAnthony C. HooperChairman of Commercial & Medical Affairs Advisory Committee and Ind. Non Executive Director
- SSShalini SharpIndependent Non-Executive Director
